You just read:

AcelRx Reports Positive Results for ARX-04 (sufentanil sublingual tablet, 30 mcg), Including in Elderly Patients and Patients with Organ Impairment, in Third Phase 3 Registration Trial, SAP303

News provided by

AcelRx Pharmaceuticals, Inc.

15 Sep, 2016, 06:30 ET